What is the current Price Target for the Fulcrum Therapeutics Inc stock?

The average Fulcrum Therapeutics Inc target price is $12.24. This is 93.06% higher than the current stock price. The highest price target is 148.42%, the lowest is -20.35%. 9 Analysts have issued a price target Fulcrum Therapeutics Inc 2026 .

How high will the Fulcrum Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Fulcrum Therapeutics Inc stock will rise. The performance of stocks, including the Fulcrum Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Fulcrum Therapeutics Inc stock today?

The performance of Fulcrum Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Fulcrum Therapeutics Inc stock fall?

The decline in Fulcrum Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Fulcrum Therapeutics Inc Forecast, price target & analysts

$6.43

1.42% today

Nasdaq, Aug 12, 07:15 pm CET

ISIN

US3596161097

Symbol

FULC

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Fulcrum Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Fulcrum Therapeutics Inc Classifications & Recommendation:

Buy

77%

Hold

15%

Sell

Fulcrum Therapeutics Inc Price Target

Target Price	$12.24
Price	$6.34
Potential	93.06% register free of charge
Number of Estimates	9

	9 Analysts have issued a price target Fulcrum Therapeutics Inc 2026 . The average Fulcrum Therapeutics Inc target price is $12.24. This is 93.06% register free of charge higher than the current stock price. The highest price target is $15.75 148.42% register free of charge , the lowest is $5.05 20.35% register free of charge .
	A rating was issued by 13 analysts: 10 Analysts recommend Fulcrum Therapeutics Inc to buy, 2 to hold and 1 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Fulcrum Therapeutics Inc stock has an average upside potential 2026 of 93.06% register free of charge . Most analysts recommend the Fulcrum Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-0.16	-1.19
	89.94%	643.75%
P/E		negative

9 Analysts have issued a Fulcrum Therapeutics Inc forecast for earnings per share. The average Fulcrum Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-0.16	89.94%
2025	$-1.19 643.75% Unlock
2026	$-1.23 3.36% Unlock
2027	$-1.01 17.89% Unlock
2028	$-1.06 4.95% Unlock
2029	$-0.80 24.53% Unlock
2030	$-0.21 73.75% Unlock
2031	$0.47 323.81% Unlock
2032	$0.93 97.87% Unlock

Current	-7.12	75.08%
2025	-5.32 25.32% Unlock
2026	-5.15 3.20% Unlock
2027	-6.29 22.14% Unlock
2028	-5.98 4.93% Unlock
2029	-7.97 33.28% Unlock
2030	-30.57 283.56% Unlock
2031	13.42 143.90% Unlock
2032	6.81 49.25% Unlock

Fulcrum Therapeutics Inc...

Current Fulcrum Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
RBC Capital	Locked ➜ Locked	Locked	Jul 30 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jul 29 2025
Piper Sandler	Locked ➜ Locked	Locked	May 29 2025
Leerink Partners	Locked ➜ Locked	Locked	May 23 2025
Cantor Fitzgerald	Locked ➜ Locked	Locked	May 15 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Feb 26 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Nov 14 2024

Analyst Rating	Date
Locked RBC Capital: Locked ➜ Locked	Jul 30 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Jul 29 2025
Locked Piper Sandler: Locked ➜ Locked	May 29 2025
Locked Leerink Partners: Locked ➜ Locked	May 23 2025
Locked Cantor Fitzgerald: Locked ➜ Locked	May 15 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Feb 26 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Nov 14 2024

Discover more stocks with a high price target

Alibaba Group Holding Ltd 29.77%

BioNTech SE - ADR 28.36%

Deutsche Telekom 27.84%

PayPal 25.45%

Walt Disney 22.35%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now